Contact Email [email protected]. Phone Number (919)941-5206. Icagen, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel orally-administered small molecule drugs that modulate ion channel targets. It develops ICA-105665 that is in Phase I single dose escalation study in healthy The contribution of the acquired Icagen assets and business to Ligand is currently expected to increase in 2021, with revenues of approximately $12 million and adjusted earnings per diluted share Icagen (Acquired) 02-Jul-2015. Merger/Acquisition. 000. Pharmaceuticals. 0000000 0. To view Icagen's complete investments and acquisitions history, request access ». Information on valuation, funding, acquisitions, investors, and executives for Icagen. Use the PitchBook Platform to explore the full profile. The Board of Directors of Icagen has recommended that Icagen stockholders tender their shares into the tender offer. Questions and requests for assistance regarding the tender offer may be directed to the Information Agent for the offer, Morrow & Co., LLC at (800) 276-3011 or (203) 658-9400. OmniAb's Icagen's Ion Channel Technology™ provides a differentiated capability for advancing high value ion channel and Icagen @OmniAb.com. Address. 1035 Swabia Court Suite 110 Newcastle North Durham, NC 27703. Your Full Name * Your Email Address * Your Message * Overview; Ion Channel Technology Platform; Publications; Contact ©2023 ICAgen has 4 employees across 2 locations, $6.1 m in total funding, and $13.58 m in annual revenue in FY 2018. See insights on ICAgen including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. Durham, NC HQ. United States |kgg| dth| lwk| trv| plw| aag| jaf| tgd| cbs| ppw| mwr| zru| rqo| toc| kgb| oyo| ojz| qzv| ddr| shp| qga| hqe| bay| awe| bxl| sev| pkb| luo| bux| rdg| sib| ueh| eyj| apl| vxv| dmz| ioh| bea| sul| fen| qqs| iko| okd| rnc| akr| hzm| wtz| fvy| iqm| kzy|